Open pilot study folowed the effect of beta-cyklodextrin-piroxikam (Flamexin) in 48 patients with back pain. Significant improvement was present in 41 %, improvement in 38,6 %, no effect in 18,2 % and worsening in 1 (2,2 %) patient.